For example, only a third of patients enrolled in the IMPower133 trial had evaluable tumor tissue, with negative PD-L1 tumor cell expression in almost all cases, while the PD-L1 expression in immune cells was negative in about half of the cases, without any correlations between PD-L1 expression levels and clinical outcomes [3]. Here, CD274 is linked to neoplasm.